TDMS Study 60968-02 Pathology Tables
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
CORE STUDY
Facility: Battelle Northwest
Chemical CAS #: 0078-84-2
Lock Date: 05/12/94
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 16 13 11 11
Natural Death 5 4 3 2
Accidently Killed 1 1
Survivors
Terminal Sacrifice 28 32 35 37
Natural Death 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (46) (44) (45) (47)
Intestine Large, Rectum (50) (49) (49) (49)
Intestine Large, Cecum (49) (46) (49) (50)
Leiomyoma 1 (2%)
Intestine Small, Duodenum (47) (45) (47) (48)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (47) (46) (48) (49)
Carcinoma 1 (2%)
Intestine Small, Ileum (49) (46) (47) (49)
Liver (49) (49) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 6 (12%) 8 (16%) 4 (8%) 3 (6%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 6 (12%) 12 (24%) 9 (18%) 8 (16%)
Hepatocellular Adenoma, Multiple 3 (6%) 2 (4%) 1 (2%)
Hepatocholangiocarcinoma 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mesentery (8) (2) (4) (3)
Hemangiosarcoma 1 (13%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (25%)
Histiocytic Sarcoma 1 (25%)
Leiomyosarcoma, Metastatic, Uterus 1 (25%)
Pancreas (50) (49) (50) (50)
Carcinoma 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Salivary Glands (50) (50) (49) (50)
Stomach, Forestomach (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Page 2
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Papilloma 3 (6%) 1 (2%)
Stomach, Glandular (49) (49) (50) (50)
Histiocytic Sarcoma 1 (2%)
Tongue (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (50) (50)
Adenoma 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (50) (49) (50) (50)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 2 (4%)
Islets, Pancreatic (50) (49) (50) (50)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Carcinoma 2 (4%)
Pituitary Gland (50) (49) (50) (49)
Pars Distalis, Adenoma 10 (20%) 9 (18%) 6 (12%) 9 (18%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (50) (50) (50) (50)
Follicular Cell, Adenoma 3 (6%) 1 (2%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (49) (50) (50)
Choriocarcinoma 1 (2%)
Cystadenocarcinoma 2 (4%)
Cystadenoma 1 (2%) 5 (10%) 2 (4%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Page 3
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Luteoma 1 (2%) 1 (2%) 1 (2%)
Teratoma Benign 1 (2%)
Teratoma Malignant 1 (2%)
Tubulostromal Adenoma 1 (2%)
Yolk Sac Carcinoma 1 (2%)
Bilateral, Cystadenoma 1 (2%)
Uterus (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 2 (4%) 2 (4%) 1 (2%) 5 (10%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (5) (5) (4) (4)
Iliac, Histiocytic Sarcoma 1 (20%) 1 (25%)
Renal, Hemangiosarcoma 1 (20%)
Renal, Histiocytic Sarcoma 1 (20%)
Lymph Node, Bronchial (42) (38) (42) (44)
Lymph Node, Mandibular (38) (38) (44) (45)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mesenteric (48) (49) (47) (47)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mediastinal (38) (38) (38) (38)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (5%)
Histiocytic Sarcoma 1 (3%)
Spleen (50) (49) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%)
Thymus (41) (43) (41) (43)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (50) (50) (50)
Carcinoma 1 (2%) 1 (2%) 2 (4%)
Skin (50) (50) (50) (50)
Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 2 (4%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1)
Fibrosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (49) (50)
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 1 (2%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 2 (4%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Mammary Gland 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Nose (50) (50) (50) (50)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (4) (2) (2)
Adenoma 1 (33%) 4 (100%) 1 (50%) 1 (50%)
Carcinoma 1 (33%) 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Ureter (1)
Transitional Epithelium, Papilloma 1 (100%)
Urinary Bladder (49) (49) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Page 5
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Leiomyosarcoma, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 3 (6%) 1 (2%)
Lymphoma Malignant 12 (24%) 13 (26%) 12 (24%) 19 (38%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 45 37 40
Total Primary Neoplasms 60 76 66 62
Total Animals with Benign Neoplasms 26 34 26 25
Total Benign Neoplasms 30 42 31 33
Total Animals with Malignant Neoplasms 25 28 26 24
Total Malignant Neoplasms 30 34 35 29
Total Animals with Metastatic Neoplasms 4 4 3 2
Total Metastatic Neoplasm 16 4 5 3
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 6 8 6 15
Natural Death 4 5 9 5
Survivors
Terminal Sacrifice 40 37 35 30
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Rectum (49) (49) (50) (49)
Sarcoma, Metastatic, Skin 1 (2%)
Intestine Large, Cecum (49) (48) (48) (48)
Leiomyoma 1 (2%)
Intestine Small, Jejunum (49) (49) (48) (46)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Small, Ileum (49) (49) (47) (48)
Liver (49) (50) (50) (50)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Cholangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 14 (29%) 12 (24%) 9 (18%) 8 (16%)
Hepatocellular Carcinoma, Multiple 3 (6%) 2 (4%) 3 (6%) 5 (10%)
Hepatocellular Adenoma 8 (16%) 13 (26%) 14 (28%) 6 (12%)
Hepatocellular Adenoma, Multiple 4 (8%) 1 (2%) 1 (2%) 1 (2%)
Hepatocholangiocarcinoma 1 (2%)
Mesentery (1) (3) (5) (3)
Hepatocellular Carcinoma, Metastatic, Liver 1 (33%)
Artery, Fibrous Histiocytoma 1 (20%)
Pancreas (50) (49) (50) (50)
Artery, Fibrous Histiocytoma 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (50) (50) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Artery, Fibrous Histiocytoma 1 (2%)
Tooth (3) (2)
Odontoma 1 (50%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Capsule, Adenoma 1 (2%) 1 (2%) 1 (2%)
Adrenal Medulla (50) (50) (50) (50)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (50) (49) (50) (50)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Parathyroid Gland (43) (41) (45) (42)
Carcinoma 1 (2%)
Thyroid Gland (50) (50) (50) (50)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 3 (6%) 2 (4%) 1 (2%) 5 (10%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Leiomyoma 1 (2%)
Seminal Vesicle (50) (50) (50) (50)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (4)
Lymph Node, Bronchial (37) (34) (33) (34)
Lymph Node, Mandibular (27) (25) (36) (31)
Page 9
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mesenteric (50) (48) (47) (47)
Lymph Node, Mediastinal (29) (34) (28) (34)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (4%)
Fibrosarcoma, Metastatic, Skin 1 (3%)
Spleen (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%)
Thymus (39) (39) (42) (36)
Fibrous Histiocytoma 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (50) (50) (50)
Fibrous Histiocytoma 1 (2%)
Mast Cell Tumor Benign 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Skeletal Muscle (1)
Hemangiosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (49) (50) (50)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 5 (10%) 2 (4%) 6 (12%) 4 (8%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 6 (12%) 6 (12%) 3 (6%) 6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Page 10
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Carcinoma, Metastatic, Thyroid Gland 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (8%) 4 (8%) 5 (10%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Artery, Fibrous Histiocytoma 1 (2%)
Artery, Mediastinum, Fibrous Histiocytoma 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%) 1 (2%)
Mediastinum, Fibrosarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Nose (50) (50) (50) (50)
Vomeronasal Organ, Adenoma 1 (2%)
Trachea (50) (50) (50) (50)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (2) (3) (2)
Adenoma 1 (33%) 1 (33%) 2 (100%)
Carcinoma 2 (67%) 2 (100%) 1 (33%)
Sarcoma 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Urinary Bladder (50) (50) (48) (50)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Artery, Fibrous Histiocytoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Lymphoma Malignant 1 (2%) 5 (10%) 1 (2%) 6 (12%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 60968-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ISOBUTYRALDEHYDE Date: 09/23/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 15:37:28
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 500 PPM 1000 PPM 2000 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 36 39 34
Total Primary Neoplasms 62 52 63 51
Total Animals with Benign Neoplasms 22 19 22 19
Total Benign Neoplasms 28 21 29 24
Total Animals with Malignant Neoplasms 28 27 22 25
Total Malignant Neoplasms 34 31 34 27
Total Animals with Metastatic Neoplasms 4 5 7 7
Total Metastatic Neoplasm 6 9 8 16
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------